MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$4,776K
Free Cash flow
-$9,058K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities of mark...
Proceeds from issuance of common...
Prepaid expenses and other curre...
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Net loss
Deferred revenue
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-8,421
-8,015
-9,074
-7,914
Loss on disposal of property and equipment
-
-
0
0
Stock-based compensation expense
2,424
2,084
2,238
2,343
Impairment loss
-
-
0
-
Depreciation and amortization
152
161
186
223
Non-cash operating lease expense
477
477
481
472
Warrant issued for services provided
-
-
-
0
Warrant modification expense
-
-
-
15
Amortization of debt discount and issuance costs
0
0
33
58
Loss on extinguishment of debt
-
-
-576
-
Net accretion and amortization of investments in marketable securities
267
244
120
0
Warrant issued for services provided
0
-
-152
-
Modification expense related to warrants
-
-
15
-
Accounts receivable
0
0
2,470
0
Contract asset
-
0
-428
-
Prepaid expenses and other current assets
-567
87
1,058
-46
Accounts payable
-204
549
-2,158
669
Accrued expenses and other current liabilities
-1,569
763
3,176
-550
Deferred revenue
-1,708
-1,708
8,539
0
Other long term assets
0
-
-
-
Operating lease liabilities
-477
-477
-483
-472
Net cash used in operating activities
-9,026
-6,497
294
-5,063
Proceeds from maturities of marketable securities
19,951
21,000
0
0
Purchases of marketable securities
34,475
23,435
30,972
0
Purchases of property and equipment
32
15
0
0
Net cash (used in)/provided by investing activities
-14,556
-2,450
-30,972
0
Proceeds from exercise of warrants issued-July Two Thousand Twenty Four And October Two Thousand Twenty Four Securities Purchase Agreement
-
-
3,869
-
Proceeds from exercise of warrants for common stock, net of issuance costs
-5
-3,864
-
-68
Proceeds from issuance of common stock-October Securities Purchase Agreement
-
-
0
-
Proceeds from issuance of common stock-July Two Thousand Twenty Five Securities Purchase Agreement
-
-
0
2,811
Proceeds from issuance of common stock and pre-funded warrants in connection with the may 2026 securities purchase agreement, net of issuance costs
18,699
-
-
-
Proceeds from issuance of common stock-July Two Thousand Twenty Four Securities Purchase Agreement
-
-
-
0
Proceeds from issuance of common stock-July Securities Purchase Agreement
-
-
0
-
Exercise of pre-funded warrants in connection with the private placement, net of issuance costs
5
-
-
-
Issuance of common stock under employee stock purchase plan
54
-
15
0
Proceeds from employee stock purchase plan
0
0
2
5
Proceeds from issuance of common stock-Private Placement Securities Purchase Agreement
-
-
49,788
-
Proceeds from exercise of series d warrants
-
-
4,530
-
Proceeds from the exercise of stock options
62
-
10
0
Tax withholdings paid on behalf of employees for net share settlement
9
32
21
7
Repayment of debt
0
0
9,472
3,750
Net cash provided by/(used in) financing activities
18,806
-27
44,852
-1,009
Net (decrease)/increase in cash, cash equivalents and restricted cash equivalents
-4,776
-8,974
14,174
-6,072
Cash, cash equivalents and restricted cash equivalents, beginning of period
9,844
18,818
4,644
4,262
Cash, cash equivalents and restricted cash equivalents, end of period
5,068
9,844
18,818
4,644
Interest income receivable included in prepaid expenses and other current assets
171
-
-
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock and...
$18,699K
Proceeds from the
exercise of stock options
$62K
Issuance of common stock
under employee stock...
$54K
(17.39%↑ Y/Y)
Exercise of pre-funded
warrants in connection...
$5K
Net cash provided
by/(used in) financing...
$18,806K
(630.79%↑ Y/Y)
Canceled cashflow
$14K
Net
(decrease)/increase in cash, cash...
-$4,776K
(-174.00%↓ Y/Y)
Canceled cashflow
$18,806K
Proceeds from maturities
of marketable...
$19,951K
(-25.42%↓ Y/Y)
Stock-based compensation
expense
$2,424K
(-66.41%↓ Y/Y)
Prepaid expenses and
other current assets
-$567K
(30.85%↑ Y/Y)
Non-cash operating lease
expense
$477K
(-50.05%↓ Y/Y)
Depreciation and
amortization
$152K
(-69.04%↓ Y/Y)
Tax withholdings
paid on behalf of...
$9K
(-70.97%↓ Y/Y)
Proceeds from exercise of
warrants for common...
-$5K
(-100.13%↓ Y/Y)
Net cash (used
in)/provided by investing...
-$14,556K
(-160.80%↓ Y/Y)
Canceled cashflow
$19,951K
Net cash used in
operating activities
-$9,026K
(35.27%↑ Y/Y)
Canceled cashflow
$3,620K
Purchases of marketable
securities
$34,475K
(1167.46%↑ Y/Y)
Purchases of property and
equipment
$32K
(-63.64%↓ Y/Y)
Net loss
-$8,421K
(64.86%↑ Y/Y)
Deferred revenue
-$1,708K
Accrued expenses and
other current...
-$1,569K
(-381.18%↓ Y/Y)
Operating lease
liabilities
-$477K
(50.00%↑ Y/Y)
Net accretion and
amortization of investments...
$267K
(68.99%↑ Y/Y)
Accounts payable
-$204K
(-146.47%↓ Y/Y)
Buy us a coffee
Rani Therapeutics Holdings, Inc. (RANI)
Rani Therapeutics Holdings, Inc. (RANI)